Gubra
Anton Willer is a highly experienced professional in the field of molecular pharmacology and hematological malignancies. Currently serving as Senior Department Manager at Gubra since September 2024, Anton previously held roles such as Team Manager and Project Leader at Symphogen, Medical Advisor for Hematology at AstraZeneca, and Senior Scientist at Symphogen. Anton's research expertise includes clinical flow cytometry, monitoring minimal residual disease in leukemia patients, and the epigenetic factors involved in cancer. Educational qualifications include a PhD in Cellular and Molecular Biology from the University of Copenhagen, with an extensive academic and research background in transcriptional regulation and hematopoiesis.
This person is not in any teams
This person is not in any offices
Gubra
Founded in 2008, we are a biotech company with two primary areas of business: Preclinical contract research organization (CRO) services and proprietary early target and drug discovery programs. Our focus is the metabolic space (e.g. obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in peptide chemistry, in vivo pharmacology, ex vivo assays, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing) and bioinformatics. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We work with some of the most interesting and loyal partners and customers from across the world in the pharmaceutical and biotech industry as well as academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.